KOSDAQMachinery439960

Cosmo Robotics

₩3,760▲ 6.82%2026-11-18 close
Market Cap
₩122B
Turnover
₩1.8B
Volume
480K
Shares out.
32.5M
PER
—
PBR
3.8×
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Revenue credibility is the first hurdle

Cosmo Robotics has a growth story built on full-lifecycle wearable rehabilitation robots, but a police probe into its 2025 revenue and a sharp decline in 2026 cumulative sales make revenue credibility the first thing to resolve.

  1. 1

    Cumulative third-quarter 2026 revenue was KRW 1.19 billion (down 37.1% year on year), with an operating loss of KRW 3.41 billion and a net loss of KRW 3.78 billion, so losses widened versus the same period last year.

  2. 2

    Police suspect that about KRW 3.5 billion of false sales was reflected in the 2025 financial statements, roughly 40% of the KRW 8.86 billion of consolidated 2025 revenue, while the company maintains that its sales were lawful.

  3. 3

    About 94% of receivables at the end of 2025 were less than three months old, and operating cash flow for 2025 was a deficit of KRW 10.59 billion.

  4. 4

    Health insurance reimbursement for rehabilitation robot therapy for patients aged 18 and under was extended from July 2026, which is expected to support hospital adoption demand.

  5. 5

    The company's targets for 2027 and 2028 are its own estimates, and whether they are met can be gauged from subsequently disclosed earnings.

02

Business structure

Cosmo Robotics is a lower-limb exoskeleton wearable rehabilitation robot maker founded in 2016, developing, manufacturing and selling products for both adults and children.

Its core products are the adult rehabilitation robot EA2 PRO, part of the Exoatlet line, and the pediatric and adolescent Bambini Teens and Bambini Kids. According to IPO materials, adult Exoatlet products accounted for 71% of consolidated 2025 revenue and pediatric Bambini products for 29%.

The company is moving beyond a hospital and rehabilitation-center B2B base toward home-use B2C sales and B2G sales to government and public institutions. IPO materials indicate plans to launch the industrial wearable COSaver and the walking-assist COSuit around the end of 2026.

Overseas revenue share is reported differently across sources, ranging from about 69% to about 86%, and the company has subsidiaries and production or R&D bases in the United States, Europe, Japan, China and Russia. The company says it is the only domestic firm holding both U.S. FDA and European CE certifications.

In adult rehabilitation, overseas competitor products targeting spinal cord injury patients are reported to have penetrated the market first, while brokers view the pediatric rehabilitation market as having few competing products.

Its revenue scale is small compared with established listed robot leaders that generate revenue in the hundreds of billions of won.

03

Recent trends

Based on consolidated DART filings, cumulative third-quarter 2026 revenue was KRW 1.19 billion (down 37.1% year on year), with an operating loss of KRW 3.41 billion and a net loss of KRW 3.78 billion, so losses widened versus the same period last year.

Consolidated 2025 revenue was KRW 8.86 billion, which the company reported as up 26.3% from the prior year, while the operating loss was KRW 8.15 billion and the net loss KRW 22.13 billion.

Press reports of first-half 2026 consolidated revenue in the KRW 2.5 billion range do not reconcile with the KRW 1.19 billion cumulative third-quarter figure, so restatement or other reconciliation needs to be checked.

The stock closed its first day on May 11, 2026 at KRW 24,000, 300% above the KRW 6,000 offering price, and touched KRW 68,500 intraday on May 15, 2026.

After the Seoul Metropolitan Police Agency's financial-crime unit searched the headquarters on September 29, 2026, the shares hit the limit-down price of KRW 7,520 on September 30 and rebounded 15.03% to close at KRW 8,650 on October 1. Co-CEO Kang Gon stepped down on June 30, 2026.

As of 07:36 KST on November 14, 2026, the share price was KRW 3,875 (down 2.39% from the prior close), with market capitalization of KRW 125.7 billion. About 94% of receivables at the end of 2025 were less than three months old, and operating cash flow in 2025 was a deficit of KRW 10.59 billion.

04

Outlook

The starting point for evaluating future results is the outcome of the police probe into whether 2025 revenue was genuine and when it was recognized. If the roughly KRW 3.5 billion under suspicion were excluded, consolidated 2025 revenue would fall to the KRW 5 billion range, a figure calculated by the press.

The auditor, Samduk Accounting Corporation, issued an unqualified opinion on the 2025 consolidated financial statements, but whether prior financial statements need correction could become an issue depending on the investigation.

The company targets consolidated revenue of KRW 30.9 billion and a return to profitability in 2027, and KRW 37.3 billion of revenue with KRW 9.4 billion of operating profit in 2028, based on its own estimates.

The most direct comparison point is how far cumulative third-quarter 2026 revenue of KRW 1.19 billion sits from these targets.

The targets depend on the FDA sales approval timing for the Bambini series in the United States, the continuation of U.S. home-use rehabilitation robot subsidies, and expansion of the home-use market.

Sources differ on the FDA sales approval status of the Bambini series, so this needs to be checked against filings or company IR materials. Receivables collection speed and whether operating cash flow improves are also key indicators of business normalization.

Once the 2026 annual business report discloses receivable balances and collection status, the cash flow trend can be tracked.

05

Bull factors

Full-lifecycle lineup and certifications

Cosmo Robotics has commercialized both the adult EA2 PRO and the pediatric Bambini Teens and Bambini Kids, which gives it a full-lifecycle lineup. According to a report by the Edaily news outlet, the company holds medical device certifications in 42 countries and generates actual sales in 18 of them. The breadth of certifications can serve as a foundation for overseas market entry.

U.S. subsidies and home-use expansion

The U.S. Centers for Medicare and Medicaid Services is reported to subsidize up to 80% of the purchase price of medical equipment, and the company is pursuing a shift from hospital-focused B2B sales to individual B2C sales.

Samsung Securities analyst Kang Young-hoon expected growth centered on the U.S. pediatric rehabilitation market as the company expands into the home-use market. This view comes from a brokerage analysis. Continuation of the U.S. subsidy could provide a foundation for home-use demand in the United States.

Pediatric demand and reimbursement

An IBK Securities analyst described Cosmo Robotics as the only company with a product portfolio covering all age groups, and said the pediatric rehabilitation robot market has virtually no competitors.

Another analysis expects hospital adoption demand to rise because health insurance reimbursement for rehabilitation robot therapy for patients aged 18 and under was extended from July 2026. Broader reimbursement coverage for pediatric use could change the cost calculus hospitals apply when adopting such robots.

06

Bear factors

False-revenue allegations under investigation

The Seoul Metropolitan Police Agency's financial-crime unit searched the headquarters on September 29, 2026 on suspicion of violating the Capital Markets Act.

Police reportedly believe about KRW 400 million of a March 2025 wearable robot sale was fabricated, and about KRW 2 billion of a December 2025 sale booked through the European subsidiary. The company says its sales were lawful and that it will cooperate with the investigation.

The auditor, Samduk Accounting Corporation, issued an unqualified opinion on the 2025 consolidated financial statements.

Rising receivables and cash burn

Receivables rose from KRW 220 million in 2022 to KRW 5.19 billion in 2025, and about 94% of the balance at the end of 2025 was less than three months old. Over the same period, the allowance-for-doubtful-accounts ratio fell from 16.4% in 2024 to 1.7% in 2025.

Operating cash flow in 2025 was a deficit of KRW 10.59 billion. Collection and provisioning have not kept pace with the growth in recognized sales.

Targets rest on untested assumptions

The company's revenue targets assume U.S. sales of the Bambini series, yet sources describe its FDA sales approval timing differently. An IPO analysis article noted an expected average selling price of roughly KRW 120 million per Bambini unit, which it said would weigh on customers.

The same article said the Bambini target market differs from that of overseas competitors focused on spinal cord injury patients. The company says its unit sales targets are conservative.

07

Risk factors

Macro & FX

A high overseas revenue share means exchange-rate moves directly affect won-translated results. Reported overseas revenue share differs by source, at about 86% in a securities report and about 69% in press coverage. Continuation of the U.S. home-use rehabilitation robot subsidy is also a core condition for U.S. demand.

Policy & regulation

Domestic and overseas medical device approvals, health insurance reimbursement and U.S. subsidy policy determine demand conditions. Sources describe the FDA sales approval timing for the Bambini series differently, so it needs to be confirmed through filings or company IR materials. Regulatory action could follow depending on the outcome of the investigation.

Market & supply

Institutional holders were subject to high mandatory holding commitments at listing, which limited tradable shares, and the float can change as each lock-up expires. The shares surged after listing, then fell sharply after late September 2026, and now trade below the offering price. With a small tradable float, volatility can stay elevated.

08

Overall view

Cosmo Robotics holds both U.S. FDA and European CE certifications and has a full-lifecycle wearable rehabilitation robot lineup, which gives its growth narrative a factual basis. U.S. home-use subsidies and the pediatric reimbursement extension effective from July 2026 are cited as supportive demand factors.

On the other side, cumulative third-quarter 2026 revenue fell 37.1% year on year to KRW 1.19 billion, and operating and net losses widened. The suspected false sales in consolidated 2025 revenue and slow receivable collection remain the largest variables in assessing earnings quality.

The company says its sales were lawful and the auditor issued an unqualified opinion, but because the investigation is ongoing, the facts have not been settled. The share price surged after listing, fell sharply from late September 2026, and the current KRW 3,875 is below the KRW 6,000 offering price.

At this stage the central questions are the credibility of revenue, cash collection, and whether the gap between company targets and actual results can narrow, rather than growth potential alone.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 13 more articles and sources
  1. alphabiz.co.kr
  2. businesskorea.co.kr
  3. econovill.com
  4. comp.wisereport.co.kr
  5. news.nate.com
  6. news.nate.com
  7. kr.investing.com
  8. news.dealsitetv.com
  9. dt.co.kr
  10. biotimes.co.kr
  11. mt.co.kr
  12. bloter.net
  13. finuts.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis